{"classes":[{"categories":[{"measurements":[{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG002","lowerLimit":"1.8","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The 90% CI was not estimable due to insufficient number of events.","groupId":"OG008","lowerLimit":"4.0","upperLimit":"NA","value":"9.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"11"}],"units":"Participants"}],"description":"Time from baseline C1 D1 to date of death due to any cause. Participants who are still alive or who are lost to follow-up will be censored at the date of last contact.","dispersionType":"90% Confidence Interval","groups":[{"description":"Dose escalation with rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG000","title":"Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG001","title":"Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC6 at Day 1 of each 21-day cycle.","id":"OG002","title":"Part 1 Cohort 3 Escalation Rebastinib 100 mg + Carboplatin AUC6"},{"description":"Dose expansion in TNBC participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG003","title":"Part 2 Cohort 1 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in TNBC participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG004","title":"Part 2 Cohort 1 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG005","title":"Part 2 Cohort 2 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG006","title":"Part 2 Cohort 2 Expansion Rebastinib 100 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG007","title":"Part 2 Cohort 3 Expansion Rebastinib 50 mg + Carboplatin AUC5"},{"description":"Dose expansion in mesothelioma participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.","id":"OG008","title":"Part 2 Cohort 3 Expansion Rebastinib 100 mg + Carboplatin AUC5"}],"paramType":"MEDIAN","populationDescription":"mITT participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline to death due to any cause (Up to 2.12 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}